{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:22:02Z","timestamp":1790698922955,"version":"4.1.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Genet"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41588-026-02550-w","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:04:03Z","timestamp":1776848643000},"page":"1112-1125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Systematic design of combination therapy by targeting master regulators of coexisting diffuse midline glioma cell states"],"prefix":"10.1038","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6307-8452","authenticated-orcid":false,"given":"Ester","family":"Calvo Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Tomassoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Obradovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1469-4704","authenticated-orcid":false,"given":"Pasquale","family":"Laise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron T.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Vlahos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna E.","family":"Minns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8590-861X","authenticated-orcid":false,"given":"Diana V.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Gallitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Jian","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2133-7281","authenticated-orcid":false,"given":"Timothy J.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6235-9463","authenticated-orcid":false,"given":"Pamela S.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theophilos","family":"Tzaridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Wechsler-Reya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4709-1088","authenticated-orcid":false,"given":"James","family":"Garvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn D.","family":"Gartrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Szalontay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stergios","family":"Zacharoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Chia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9451-2685","authenticated-orcid":false,"given":"Zhiguo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4742-3679","authenticated-orcid":false,"given":"Andrea","family":"Califano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6968-600X","authenticated-orcid":false,"given":"Jovana","family":"Pavisic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"2550_CR1","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/nm.3915","volume":"21","author":"AA Alizadeh","year":"2015","unstructured":"Alizadeh, A. A. et al. Toward understanding and exploiting tumor heterogeneity. Nat. Med. 21, 846\u2013853 (2015).","journal-title":"Nat. Med."},{"key":"2550_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613\u2013628 (2017).","journal-title":"Cell"},{"key":"2550_CR3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk, A., Janiszewska, M. & Polyak, K. Intratumor heterogeneity: the Rosetta Stone of therapy resistance. Cancer Cell 37, 471\u2013484 (2020).","journal-title":"Cancer Cell"},{"key":"2550_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81\u201394 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2550_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-01001-x","volume":"13","author":"C Fustero-Torre","year":"2021","unstructured":"Fustero-Torre, C. et al. Beyondcell: targeting cancer therapeutic heterogeneity in single-cell RNA-seq data. Genome Med. 13, 187 (2021).","journal-title":"Genome Med."},{"key":"2550_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ccell.2024.03.004","volume":"42","author":"H Yang","year":"2024","unstructured":"Yang, H. et al. Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer. Cancer Cell 42, 535\u2013551.e8 (2024).","journal-title":"Cancer Cell"},{"key":"2550_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00894-y","volume":"13","author":"W Zhao","year":"2021","unstructured":"Zhao, W. et al. Deconvolution of cell type-specific drug responses in human tumor tissue with single-cell RNA-seq. Genome Med. 13, 82 (2021).","journal-title":"Genome Med."},{"key":"2550_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.csbj.2022.11.055","volume":"21","author":"C-Y Hsieh","year":"2023","unstructured":"Hsieh, C.-Y. et al. scDrug: from single-cell RNA-seq to drug response prediction. Comput. Struct. Biotechnol. J. 21, 150\u2013157 (2023).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"2550_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52980-5","volume":"15","author":"A Ianevski","year":"2024","unstructured":"Ianevski, A. et al. Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones. Nat. Commun. 15, 8579 (2024).","journal-title":"Nat. Commun."},{"key":"2550_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-023-01256-6","volume":"15","author":"C Tang","year":"2023","unstructured":"Tang, C. et al. Personalized tumor combination therapy optimization using the single-cell transcriptome. Genome Med. 15, 105 (2023).","journal-title":"Genome Med."},{"key":"2550_CR11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc.2016.124","volume":"17","author":"A Califano","year":"2017","unstructured":"Califano, A. & Alvarez, M. J. The recurrent architecture of tumour initiation, progression and drug sensitivity. Nat. Rev. Cancer 17, 116\u2013130 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"2550_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nature08712","volume":"463","author":"MS Carro","year":"2010","unstructured":"Carro, M. S. et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 463, 318\u2013325 (2010).","journal-title":"Nature"},{"key":"2550_CR13","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2020.11.045","volume":"184","author":"EO Paull","year":"2021","unstructured":"Paull, E. O. et al. A modular master regulator landscape controls cancer transcriptional identity. Cell 184, 334\u2013351.e20 (2021).","journal-title":"Cell"},{"key":"2550_CR14","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccr.2014.03.017","volume":"25","author":"A Aytes","year":"2014","unstructured":"Aytes, A. et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 25, 638\u2013651 (2014).","journal-title":"Cancer Cell"},{"key":"2550_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s43018-022-00489-5","volume":"4","author":"TZ Zeleke","year":"2022","unstructured":"Zeleke, T. Z. et al. Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nat. Cancer 4, 257\u2013275 (2022).","journal-title":"Nat. Cancer"},{"key":"2550_CR16","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/s41588-018-0138-4","volume":"50","author":"MJ Alvarez","year":"2018","unstructured":"Alvarez, M. J. et al. A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nat. Genet. 50, 979\u2013989 (2018).","journal-title":"Nat. Genet."},{"key":"2550_CR17","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1158\/2159-8290.CD-22-1020","volume":"13","author":"PS Mundi","year":"2023","unstructured":"Mundi, P. S. et al. A transcriptome-based precision oncology platform for patient\u2013therapy alignment in a diverse set of treatment-resistant malignancies. Cancer Discov. 13, 1386\u20131407 (2023).","journal-title":"Cancer Discov."},{"key":"2550_CR18","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1186\/1471-2105-7-S1-S7","volume":"7","author":"AA Margolin","year":"2006","unstructured":"Margolin, A. A. et al. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics 7, S7 (2006).","journal-title":"BMC Bioinformatics"},{"key":"2550_CR19","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1093\/bioinformatics\/btw216","volume":"32","author":"A Lachmann","year":"2016","unstructured":"Lachmann, A., Giorgi, F. M., Lopez, G. & Califano, A. ARACNe-AP: gene network reverse engineering through adaptive partitioning inference of mutual information. Bioinformatics 32, 2233\u20132235 (2016).","journal-title":"Bioinformatics"},{"key":"2550_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1126\/science.aao4750","volume":"360","author":"MG Filbin","year":"2018","unstructured":"Filbin, M. G. et al. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science 360, 331\u2013335 (2018).","journal-title":"Science"},{"key":"2550_CR21","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1038\/s41588-022-01236-3","volume":"54","author":"I Liu","year":"2022","unstructured":"Liu, I. et al. The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location. Nat. Genet. 54, 1881\u20131894 (2022).","journal-title":"Nat. Genet."},{"key":"2550_CR22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/ng.2936","volume":"46","author":"P Buczkowicz","year":"2014","unstructured":"Buczkowicz, P. et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat. Genet. 46, 451\u2013456 (2014).","journal-title":"Nat. Genet."},{"key":"2550_CR23","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.cancergen.2015.04.008","volume":"208","author":"E Panditharatna","year":"2015","unstructured":"Panditharatna, E., Yaeger, K., Kilburn, L. B., Packer, R. J. & Nazarian, J. Clinicopathology of diffuse intrinsic pontine glioma and its redefined genomic and epigenomic landscape. Cancer Genet. 208, 367\u2013373 (2015).","journal-title":"Cancer Genet."},{"key":"2550_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3389\/fonc.2017.00057","volume":"7","author":"DH Lapin","year":"2017","unstructured":"Lapin, D. H., Tsoli, M. & Ziegler, D. S. Genomic insights into diffuse intrinsic pontine glioma. Front. Oncol. 7, 57 (2017).","journal-title":"Front. Oncol."},{"key":"2550_CR25","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10833","volume":"482","author":"J Schwartzentruber","year":"2012","unstructured":"Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226\u2013231 (2012).","journal-title":"Nature"},{"key":"2550_CR26","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/ng.2938","volume":"46","author":"G Wu","year":"2014","unstructured":"Wu, G. et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat. Genet. 46, 444\u2013450 (2014).","journal-title":"Nat. Genet."},{"key":"2550_CR27","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2017.75.9308","volume":"36","author":"LM Hoffman","year":"2018","unstructured":"Hoffman, L. M. et al. Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the International and European Society for Pediatric Oncology DIPG Registries. J. Clin. Oncol. 36, 1963\u20131972 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2550_CR28","first-page":"185","volume":"24","author":"AM Kaplan","year":"1996","unstructured":"Kaplan, A. M. et al. Brainstem gliomas in children. A children\u2019s cancer group review of 119 cases. Pediatr. Neurosurg. 24, 185\u2013192 (1996).","journal-title":"Pediatr. Neurosurg."},{"key":"2550_CR29","doi-asserted-by":"publisher","first-page":"eaaw0064","DOI":"10.1126\/scitranslmed.aaw0064","volume":"11","author":"GL Lin","year":"2019","unstructured":"Lin, G. L. et al. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Sci. Transl. Med. 11, eaaw0064 (2019).","journal-title":"Sci. Transl. Med."},{"key":"2550_CR30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41388-021-02102-y","volume":"41","author":"IJ Findlay","year":"2022","unstructured":"Findlay, I. J. et al. Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies. Oncogene 41, 461\u2013475 (2022).","journal-title":"Oncogene"},{"key":"2550_CR31","doi-asserted-by":"publisher","first-page":"100899","DOI":"10.1016\/j.neo.2023.100899","volume":"40","author":"A Noon","year":"2023","unstructured":"Noon, A. & Galban, S. Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas. Neoplasia 40, 100899 (2023).","journal-title":"Neoplasia"},{"key":"2550_CR32","doi-asserted-by":"publisher","unstructured":"Mayr, L. et al. Effective targeting of PDGFRA-altered high-grade glioma with avapritinib. Cancer Cell https:\/\/doi.org\/10.1016\/j.ccell.2025.02.018 (2025).","DOI":"10.1016\/j.ccell.2025.02.018"},{"key":"2550_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-015-0269-0","volume":"4","author":"LM Hoffman","year":"2016","unstructured":"Hoffman, L. M. et al. Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics. Acta Neuropathol. Commun. 4, 1 (2016).","journal-title":"Acta Neuropathol. Commun."},{"key":"2550_CR34","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nrc3811","volume":"14","author":"C Jones","year":"2014","unstructured":"Jones, C. & Baker, S. J. Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat. Rev. Cancer 14, 651\u2013661 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"2550_CR35","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nm.3855","volume":"21","author":"CS Grasso","year":"2015","unstructured":"Grasso, C. S. et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat. Med. 21, 555\u2013559 (2015).","journal-title":"Nat. Med."},{"key":"2550_CR36","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.ccell.2017.03.011","volume":"31","author":"S Nagaraja","year":"2017","unstructured":"Nagaraja, S. et al. Transcriptional dependencies in diffuse intrinsic pontine glioma. Cancer Cell 31, 635\u2013652.e6 (2017).","journal-title":"Cancer Cell"},{"key":"2550_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03843-3","volume":"9","author":"H Ding","year":"2018","unstructured":"Ding, H. et al. Quantitative assessment of protein activity in orphan tissues and single cells using the metaVIPER algorithm. Nat. Commun. 9, 1471 (2018).","journal-title":"Nat. Commun."},{"key":"2550_CR38","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/ng.3593","volume":"48","author":"MJ Alvarez","year":"2016","unstructured":"Alvarez, M. J. et al. Functional characterization of somatic mutations in cancer using network-based inference of protein activity. Nat. Genet. 48, 838\u2013847 (2016).","journal-title":"Nat. Genet."},{"key":"2550_CR39","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/ng1532","volume":"37","author":"K Basso","year":"2005","unstructured":"Basso, K. et al. Reverse engineering of regulatory networks in human B cells. Nat. Genet. 37, 382\u2013390 (2005).","journal-title":"Nat. Genet."},{"key":"2550_CR40","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396\u20131401 (2014).","journal-title":"Science"},{"key":"2550_CR41","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1016\/j.cell.2021.04.038","volume":"184","author":"A Obradovic","year":"2021","unstructured":"Obradovic, A. et al. Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell 184, 2988\u20133005.e16 (2021).","journal-title":"Cell"},{"key":"2550_CR42","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neuroscience.2014.01.051","volume":"276","author":"L Magri","year":"2014","unstructured":"Magri, L. et al. c-Myc-dependent transcriptional regulation of cell cycle and nucleosomal histones during oligodendrocyte differentiation. Neuroscience 276, 72\u201386 (2014).","journal-title":"Neuroscience"},{"key":"2550_CR43","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11481-013-9517-x","volume":"9","author":"PD Pozniak","year":"2014","unstructured":"Pozniak, P. D., White, M. K. & Khalili, K. TNF-\u03b1\/NF-\u03baB signaling in the CNS: possible connection to EPHB2. J. Neuroimmune Pharmacol. 9, 133\u2013141 (2014).","journal-title":"J. Neuroimmune Pharmacol."},{"key":"2550_CR44","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.3390\/cimb44050149","volume":"44","author":"S Wang","year":"2022","unstructured":"Wang, S., Wang, Y. & Zou, S. A glance at the molecules that regulate oligodendrocyte myelination. Curr. Issues Mol. Biol. 44, 2194\u20132216 (2022).","journal-title":"Curr. Issues Mol. Biol."},{"key":"2550_CR45","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1083\/jcb.200202002","volume":"158","author":"S Genoud","year":"2002","unstructured":"Genoud, S. et al. Notch1 control of oligodendrocyte differentiation in the spinal cord. J. Cell Biol. 158, 709\u2013718 (2002).","journal-title":"J. Cell Biol."},{"key":"2550_CR46","doi-asserted-by":"publisher","first-page":"8321","DOI":"10.1523\/JNEUROSCI.1377-20.2021","volume":"41","author":"MA Jeffries","year":"2021","unstructured":"Jeffries, M. A. et al. mTOR signaling regulates metabolic function in oligodendrocyte precursor cells and promotes efficient brain remyelination in the cuprizone model. J. Neuroscience 41, 8321\u20138337 (2021).","journal-title":"J. Neuroscience"},{"key":"2550_CR47","doi-asserted-by":"publisher","first-page":"8432","DOI":"10.1523\/JNEUROSCI.1105-14.2014","volume":"34","author":"F Lebrun-Julien","year":"2014","unstructured":"Lebrun-Julien, F. et al. Balanced mTORC1 activity in oligodendrocytes is required for accurate CNS myelination. J. Neurosci. 34, 8432\u20138448 (2014).","journal-title":"J. Neurosci."},{"key":"2550_CR48","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/453020","volume":"2015","author":"VP \u010coki\u0107","year":"2015","unstructured":"\u010coki\u0107, V. P. et al. Proinflammatory cytokine IL-6 and JAK\u2013STAT signaling pathway in myeloproliferative neoplasms. Mediators Inflamm. 2015, 453020 (2015).","journal-title":"Mediators Inflamm."},{"key":"2550_CR49","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3892\/br.2014.401","volume":"3","author":"T WANG","year":"2015","unstructured":"WANG, T. et al. The role of the JAK\u2013STAT pathway in neural stem cells, neural progenitor cells and reactive astrocytes after spinal cord injury. Biomed. Rep. 3, 141\u2013146 (2015).","journal-title":"Biomed. Rep."},{"key":"2550_CR50","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/jnr.20044","volume":"76","author":"S Okada","year":"2004","unstructured":"Okada, S. et al. Blockade of interleukin-6 receptor suppresses reactive astrogliosis and ameliorates functional recovery in experimental spinal cord injury. J. Neurosci. Res. 76, 265\u2013276 (2004).","journal-title":"J. Neurosci. Res."},{"key":"2550_CR51","doi-asserted-by":"publisher","first-page":"155582","DOI":"10.1016\/j.cyto.2021.155582","volume":"144","author":"KK Kummer","year":"2021","unstructured":"Kummer, K. K., Zeidler, M., Kalpachidou, T. & Kress, M. Role of IL-6 in the regulation of neuronal development, survival and function. Cytokine 144, 155582 (2021).","journal-title":"Cytokine"},{"key":"2550_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01675-8","volume":"25","author":"BS Katzenellenbogen","year":"2023","unstructured":"Katzenellenbogen, B. S., Guillen, V. S. & Katzenellenbogen, J. A. Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer. Breast Cancer Res. 25, 76 (2023).","journal-title":"Breast Cancer Res."},{"key":"2550_CR53","doi-asserted-by":"publisher","first-page":"D882","DOI":"10.1093\/nar\/gkz1062","volume":"48","author":"Y Luo","year":"2020","unstructured":"Luo, Y. et al. New developments on the Encyclopedia of DNA Elements (ENCODE) data portal. Nucleic Acids Res. 48, D882\u2013D889 (2020).","journal-title":"Nucleic Acids Res."},{"key":"2550_CR54","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature11247","volume":"489","author":"ENCODE Project Consortium.","year":"2012","unstructured":"ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57\u201374 (2012).","journal-title":"Nature"},{"key":"2550_CR55","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/s41588-019-0509-5","volume":"51","author":"MJ Alvarez","year":"2019","unstructured":"Alvarez, M. J. et al. Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines'. Nat. Genet. 51, 1427\u20131428 (2019).","journal-title":"Nat. Genet."},{"key":"2550_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00136-z","volume":"8","author":"EC Bush","year":"2017","unstructured":"Bush, E. C. et al. PLATE-seq for genome-wide regulatory network analysis of high-throughput screens. Nat. Commun. 8, 105 (2017).","journal-title":"Nat. Commun."},{"key":"2550_CR57","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1158\/2159-8290.CD-22-0342","volume":"13","author":"A Vasciaveo","year":"2023","unstructured":"Vasciaveo, A. et al. OncoLoop: a network-based precision cancer medicine framework. Cancer Discov. 13, 386\u2013409 (2023).","journal-title":"Cancer Discov"},{"key":"2550_CR58","first-page":"2251","volume":"8","author":"I Lugowska","year":"2015","unstructured":"Lugowska, I., Kose\u0142a-Paterczyk, H., Kozak, K. & Rutkowski, P. Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco. Targets Ther. 8, 2251\u20132259 (2015).","journal-title":"Onco. Targets Ther."},{"key":"2550_CR59","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3906\/biy-1701-26","volume":"41","author":"A\u0130 Uba","year":"2017","unstructured":"Uba, A. \u0130 & Yelek\u00e7i, K. Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors. Turk. J. Biol. 41, 901\u2013918 (2017).","journal-title":"Turk. J. Biol."},{"key":"2550_CR60","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1182\/blood-2014-05-573741","volume":"125","author":"SK Kumar","year":"2015","unstructured":"Kumar, S. K. et al. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood 125, 443\u2013448 (2015).","journal-title":"Blood"},{"key":"2550_CR61","first-page":"100221","volume":"25","author":"C Cattrini","year":"2020","unstructured":"Cattrini, C., Capaia, M., Boccardo, F. & Barboro, P. Etoposide and topoisomerase II inhibition for aggressive prostate cancer: data from a translational study. Cancer Treat. Res. Commun. 25, 100221 (2020).","journal-title":"Cancer Treat. Res. Commun."},{"key":"2550_CR62","doi-asserted-by":"publisher","first-page":"922928","DOI":"10.3389\/fonc.2022.922928","volume":"12","author":"K Schwark","year":"2022","unstructured":"Schwark, K. et al. Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: pre-clinical models and precision medicine. Front. Oncol. 12, 922928 (2022).","journal-title":"Front. Oncol."},{"key":"2550_CR63","doi-asserted-by":"publisher","first-page":"400","DOI":"10.6004\/jadpro.2022.13.4.4","volume":"13","author":"MM Waggoner","year":"2022","unstructured":"Waggoner, M. M., Katsetos, P.-C. J., Thomas, M. M. P.-C. E., Galinsky, B. M. A.-C. I. & Fox, P.-C. H. Practical management of the venetoclax-treated patient in chronic lymphocytic leukemia and acute myeloid leukemia. J. Adv. Pract. Oncol. 13, 400\u2013415 (2022).","journal-title":"J. Adv. Pract. Oncol."},{"key":"2550_CR64","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/17512433.2019.1661775","volume":"12","author":"N Federman","year":"2019","unstructured":"Federman, N. & McDermott, R. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer. Expert Rev. Clin. Pharmacol. 12, 931\u2013939 (2019).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"2550_CR65","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13046-019-1289-6","volume":"38","author":"D Han","year":"2019","unstructured":"Han, D. et al. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. J. Exp. Clin. Cancer Res. 38, 289 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2550_CR66","doi-asserted-by":"publisher","first-page":"e0169485","DOI":"10.1371\/journal.pone.0169485","volume":"12","author":"T Hennika","year":"2017","unstructured":"Hennika, T. et al. Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models. PLoS ONE 12, e0169485 (2017).","journal-title":"PLoS ONE"},{"key":"2550_CR67","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1179\/1743132812Y.0000000005","volume":"34","author":"R D\u2019Amico","year":"2012","unstructured":"D\u2019Amico, R. et al. The addition of sunitinib to radiation delays tumor growth in a murine model of glioblastoma. Neurol. Res. 34, 252\u2013261 (2012).","journal-title":"Neurol. Res."},{"key":"2550_CR68","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 50, W739\u2013W743 (2022).","journal-title":"Nucleic Acids Res."},{"key":"2550_CR69","doi-asserted-by":"publisher","first-page":"5393","DOI":"10.1158\/0008-5472.CAN-20-1655","volume":"80","author":"JM Rusert","year":"2020","unstructured":"Rusert, J. M. et al. Functional precision medicine identifies new therapeutic candidates for medulloblastoma. Cancer Res. 80, 5393\u20135407 (2020).","journal-title":"Cancer Res."},{"key":"2550_CR70","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/nmeth.4463","volume":"14","author":"S Aibar","year":"2017","unstructured":"Aibar, S. et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods 14, 1083\u20131086 (2017).","journal-title":"Nat. Methods"},{"key":"2550_CR71","doi-asserted-by":"publisher","first-page":"e12776","DOI":"10.1371\/journal.pone.0012776","volume":"5","author":"VA Huynh-Thu","year":"2010","unstructured":"Huynh-Thu, V. A., Irrthum, A., Wehenkel, L. & Geurts, P. Inferring regulatory networks from expression data using tree-based methods. PLoS ONE 5, e12776 (2010).","journal-title":"PLoS ONE"},{"key":"2550_CR72","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cels.2017.08.014","volume":"5","author":"TE Chan","year":"2017","unstructured":"Chan, T. E., Stumpf, M. P. H. & Babtie, A. C. Gene regulatory network inference from single-cell data using multivariate information measures. Cell Syst. 5, 251\u2013267.e3 (2017).","journal-title":"Cell Syst."},{"key":"2550_CR73","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1093\/bioinformatics\/btac117","volume":"38","author":"C Skok Gibbs","year":"2022","unstructured":"Skok Gibbs, C. et al. High-performance single-cell gene regulatory network inference at scale: the Inferelator 3.0. Bioinformatics 38, 2519\u20132528 (2022).","journal-title":"Bioinformatics"},{"key":"2550_CR74","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/s41586-022-05688-9","volume":"614","author":"K Kamimoto","year":"2023","unstructured":"Kamimoto, K. et al. Dissecting cell identity via network inference and in silico gene perturbation. Nature 614, 742\u2013751 (2023).","journal-title":"Nature"},{"key":"2550_CR75","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41525-020-00151-y","volume":"5","author":"AE Teschendorff","year":"2020","unstructured":"Teschendorff, A. E. & Wang, N. Improved detection of tumor suppressor events in single-cell RNA-seq data. NPJ Genom. Med. 5, 43 (2020).","journal-title":"NPJ Genom. Med."},{"key":"2550_CR76","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1093\/bioinformatics\/btx139","volume":"33","author":"D Schlauch","year":"2017","unstructured":"Schlauch, D., Paulson, J. N., Young, A., Glass, K. & Quackenbush, J. Estimating gene regulatory networks with pandaR. Bioinformatics 33, 2232\u20132234 (2017).","journal-title":"Bioinformatics"},{"key":"2550_CR77","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1158\/2159-8290.CD-16-0861","volume":"8","author":"P Rajbhandari","year":"2018","unstructured":"Rajbhandari, P. et al. Cross-cohort analysis identifies a TEAD4\u2013MYCN positive feedback loop as the core regulatory element of high-risk neuroblastoma. Cancer Discov. 8, 582\u2013599 (2018).","journal-title":"Cancer Discov."},{"key":"2550_CR78","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/oncolo\/oyae118","volume":"29","author":"JK Jamison","year":"2024","unstructured":"Jamison, J. K. et al. Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors. Oncologist 29, 817\u2013e1213 (2024).","journal-title":"Oncologist"},{"key":"2550_CR79","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41416-018-0251-2","volume":"119","author":"DS Ziegler","year":"2018","unstructured":"Ziegler, D. S. et al. Brief report: potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma. Br. J. Cancer 119, 693\u2013696 (2018).","journal-title":"Br. J. Cancer"},{"key":"2550_CR80","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S1470-2045(18)30119-0","volume":"19","author":"TW Laetsch","year":"2018","unstructured":"Laetsch, T. W. et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study. Lancet Oncol. 19, 705\u2013714 (2018).","journal-title":"Lancet Oncol."},{"key":"2550_CR81","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ccell.2023.04.003","volume":"41","author":"A Obradovic","year":"2023","unstructured":"Obradovic, A. et al. Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators. Cancer Cell 41, 933\u2013949.e11 (2023).","journal-title":"Cancer Cell"},{"key":"2550_CR82","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","volume":"171","author":"AC Palmer","year":"2017","unstructured":"Palmer, A. C. & Sorger, P. K. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell 171, 1678\u20131691.e13 (2017).","journal-title":"Cell"},{"key":"2550_CR83","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10555-020-09940-4","volume":"40","author":"C Riess","year":"2021","unstructured":"Riess, C. et al. Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma\u2014Backbone or add-on in immune-oncology? Cancer Metastasis Rev. 40, 153\u2013171 (2021).","journal-title":"Cancer Metastasis Rev."},{"key":"2550_CR84","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1002\/mco2.181","volume":"3","author":"GH Liu","year":"2022","unstructured":"Liu, G. H., Chen, T., Zhang, X., Ma, X. L. & Shi, H. S. Small molecule inhibitors targeting the cancers. MedComm 3, e181 (2022).","journal-title":"MedComm"},{"key":"2550_CR85","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/glia.23767","volume":"68","author":"E Gerrits","year":"2020","unstructured":"Gerrits, E., Heng, Y., Boddeke, E. W. G. M. & Eggen, B. J. L. Transcriptional profiling of microglia; current state of the art and future perspectives. Glia 68, 740\u2013755 (2020).","journal-title":"Glia"},{"key":"2550_CR86","unstructured":"Pacific Pediatric Neuro-Oncology Consortium (PNOC). https:\/\/pnoc.us"},{"key":"2550_CR87","unstructured":"The Childhood Brain Tumor Tissue Consortium (CBTTC). https:\/\/cbtn.org"},{"key":"2550_CR88","doi-asserted-by":"publisher","unstructured":"Vlahos, L. et al. Systematic, protein activity-based characterization of single cell state. Preprint at https:\/\/doi.org\/10.1101\/2021.05.20.445002 (2023).","DOI":"10.1101\/2021.05.20.445002"},{"key":"2550_CR89","doi-asserted-by":"publisher","first-page":"100492","DOI":"10.1016\/j.xcrm.2021.100492","volume":"3","author":"EF Douglass","year":"2022","unstructured":"Douglass, E. F. et al. A community challenge for a pancancer drug mechanism of action inference from perturbational profile data. Cell Rep. Med. 3, 100492 (2022).","journal-title":"Cell Rep. Med."},{"key":"2550_CR90","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cell.2015.05.056","volume":"162","author":"JH Woo","year":"2015","unstructured":"Woo, J. H. et al. Elucidating compound mechanism of action by network perturbation analysis. Cell 162, 441\u2013451 (2015).","journal-title":"Cell"},{"key":"2550_CR91","unstructured":"Schlattmann, P. Medical Applications of Finite Mixture Models (Springer, 2009)."},{"key":"2550_CR92","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/nbt1406","volume":"26","author":"CB Do","year":"2008","unstructured":"Do, C. B. & Batzoglou, S. What is the expectation maximization algorithm? Nat. Biotechnol. 26, 897\u2013899 (2008).","journal-title":"Nat. Biotechnol."}],"container-title":["Nature Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41588-026-02550-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-026-02550-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-026-02550-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:02:28Z","timestamp":1778778148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41588-026-02550-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":92,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2550"],"URL":"https:\/\/doi.org\/10.1038\/s41588-026-02550-w","relation":{},"ISSN":["1061-4036","1546-1718"],"issn-type":[{"value":"1061-4036","type":"print"},{"value":"1546-1718","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"16 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.C. is a founder, equity holder and consultant of DarwinHealth, a company that has licensed some of the algorithms used in this paper from Columbia University. Columbia University is also an equity holder in DarwinHealth. P.L. and L.T. work at DarwinHealth. S.Z. was the senior director of pediatric oncology at Bristol Myers Squibb during this study, but no longer holds that position. P.S.B. is a consultant at Accordant Health Services and has received research funding from GPCR Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}